文献速递炎症性肠病

综述:超越炎症性肠病治疗天花板——基于机制的治疗定位与新兴策略

Review Article: Beyond the Therapeutic Ceiling in Inflammatory Bowel Disease-Mechanism-Based Positioning and Emerging Therapeutic Strategies.
PubMed 文献 · Aliment Pharmacol Ther · 2026-10-02

本综述检索PubMed、Ovid MEDLINE、Embase及主要国际会议摘要,聚焦炎症性肠病基于机制的治疗定位、疾病修饰、难治性疾病及新兴策略。比较研究强化了选择性IL-23抑制剂作为基础治疗的地位,口服小分子药物持续扩展;靶向TL1A、纤维化及先进联合治疗有望改善难治性疾病结局,但最佳治疗顺序、患者选择、长期安全性及疾病修饰仍是挑战。

要点

  • 选择性IL-23抑制剂经比较研究支持作为IBD基础治疗。
  • 口服小分子药物机制与便利性持续扩展。
  • 靶向TL1A、纤维化及先进联合治疗为难治性疾病提供新方向。

核心结论

  • 当代IBD管理日益由基于机制的治疗定位定义,而非单纯扩大治疗选择。
  • 比较有效性研究、新靶点及治疗策略的进展有望进一步个体化诊疗并改善长期结局。

研究设计与样本

  • 综述检索PubMed、Ovid MEDLINE、Embase及主要国际会议摘要,纳入关键临床试验、长期扩展研究、比较有效性研究、真实世界证据及新兴治疗进展。

主要发现

  • 比较研究强化了选择性IL-23抑制剂作为IBD基础治疗的地位。
  • 口服小分子药物持续扩展,具有新机制和更好便利性。
  • 靶向TL1A、纤维化及先进联合治疗有望进一步改善结局,尤其难治性疾病。

临床怎么用

  • 临床决策应基于机制将药物定位到治疗算法中,而非仅按可及性选择。
  • 对难治性IBD可关注靶向TL1A、纤维化及先进联合治疗等新兴策略。

局限性

  • 最佳治疗顺序、患者选择、长期安全性及疾病修饰仍存挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Therapeutic options for inflammatory bowel disease (IBD) have expanded rapidly with the introduction of selective interleukin (IL)-23 inhibitors, Janus kinase inhibitors, sphingosine-1-phosphate receptor modulators, and several emerging therapeutic classes. Consequently, the major clinical challenge has shifted from developing effective therapies to determining how best to position them within increasingly complex treatment algorithms. AIMS: To review the contemporary and emerging therapeutic landscape in IBD, focusing on mechanism-based treatment positioning, disease modification, refractory disease, and novel therapeutic strategies that may overcome the current therapeutic ceiling. METHODS: We performed a comprehensive review of PubMed, Ovid MEDLINE, Embase, and major international conference proceedings to identify pivotal clinical trials, long-term extension studies, comparative effectiveness studies, real-world evidence, and emerging therapeutic developments in IBD. RESULTS: Comparative studies have strengthened the positioning of selective iL-23 inhibitors as foundational therapies in IBD, while oral small molecules continue to expand with novel mechanisms and improved convenience. Emerging strategies targeting TL1A, fibrosis and advanced combination therapy offer the potential to further improve outcomes, particularly in refractory disease. However, important challenges remain regarding optimal treatment sequencing, patient selection, long-term safety and disease modification. CONCLUSION: Contemporary IBD management is increasingly defined by mechanism-based therapeutic positioning rather than simply expanding treatment options. Ongoing advances in comparative effectiveness research, novel therapeutic targets, and treatment strategies have the potential to further individualise care and improve long-term patient outcomes.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Subhaharan D, Subramanian S. Review Article: Beyond the Therapeutic Ceiling in Inflammatory Bowel Disease-Mechanism-Based Positioning and Emerging Therapeutic Strategies. Aliment Pharmacol Ther. 2026. PMID: 42827330. doi:10.1111/apt.70978

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。